相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
Tadeusz Robak et al.
CANCERS (2022)
Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2021)
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
Matthew S. Davids et al.
LEUKEMIA (2021)
Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial
Javier Pinilla Ibarz et al.
BLOOD (2021)
A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease(MRD)-Driven, Time-Limited Approach
Lindsey E. Roeker et al.
BLOOD (2021)
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies
Shuo Ma et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)
Ryan C. Lynch et al.
BLOOD (2021)
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia
Ishwarya Murali et al.
BLOOD (2021)
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Chiara Tarantelli et al.
CANCERS (2021)
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity
Sarah Christine Elisabeth Wright et al.
CANCERS (2021)
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL
Valerio Guarente et al.
CANCERS (2021)
A phase Ib study result of HMPL-689, a PI3Kδ inhibitor, in Chinese patients with relapsed/refractory lymphoma
J. Cao et al.
ANNALS OF ONCOLOGY (2021)
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Coastal: A phase 3 study of the PI3Kd inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL).
Wojciech Jurczak et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches
Matteo Caforio et al.
CANCERS (2021)
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Morton Coleman et al.
LEUKEMIA & LYMPHOMA (2021)
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Matthew S. Davids et al.
CLINICAL CANCER RESEARCH (2020)
Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.
Andrew David Zelenetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial.
Huaqing Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation
Anne-Katrien Stark et al.
JOURNAL OF IMMUNOLOGY (2020)
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
Lenka Sedlarikova et al.
FRONTIERS IN ONCOLOGY (2020)
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
Kamira Maharaj et al.
BLOOD ADVANCES (2020)
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen et al.
CANCERS (2020)
Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
Anthony R. Mato et al.
BLOOD (2020)
SHC014748M, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia
Lei Fan et al.
NEOPLASIA (2020)
A phase I study of HMPL-689, a small molecule selective inhibitor of phosphoinositide 3-kinase-delta, inpatients with relapsed or refractory lymphoma
Tunde Lawrence et al.
CANCER RESEARCH (2020)
A Phase 1 Study of HMPL-689, a Small Molecule, Highly Selective, and Potent Inhibitor of Phosphoinositide 3 Kinase-Delta, in Patients with Relapsed or Refractory Lymphoma
Tunde Lawrence et al.
BLOOD (2020)
Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas
Junning Cao et al.
BLOOD (2020)
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O plus Chl) in Patients with Treatment Naive (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study
John G. Gribben et al.
BLOOD (2020)
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
Andres Forero-Torres et al.
BLOOD (2019)
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
Stalin Chellappa et al.
JOURNAL OF IMMUNOLOGY (2019)
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
Annika Scheffold et al.
BLOOD (2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning et al.
BLOOD (2019)
Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models
Ofir Moreno et al.
TARGETED ONCOLOGY (2019)
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia
Ian W. Flinn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Bartosz Pula et al.
CANCERS (2019)
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
Matthew S. Davids et al.
LANCET HAEMATOLOGY (2019)
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A. Burris et al.
LANCET ONCOLOGY (2018)
Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration
Ahmed Y. Ali et al.
LEUKEMIA (2018)
Duvelisib, an oral dual PI3K-, inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
Susan O'Brien et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Initial results of a dose escalation study of a selective and structurally differentiated PI3K delta inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Jacob Drobnyk Soumerai et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 delta, Following Single Ascending Dose Administration to Healthy Volunteers
Ofir Moreno et al.
CLINICAL THERAPEUTICS (2018)
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Steven E. Coutre et al.
HEMASPHERE (2018)
Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model
Shih-Shih Chen et al.
BLOOD (2018)
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Ian W. Flinn et al.
BLOOD (2018)
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies
Changchun Deng et al.
BLOOD (2017)
Duvelisib: a phosphoinositide-3 kinase/inhibitor for chronic lymphocytic leukemia
Hima V. Vangapandu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz et al.
LANCET ONCOLOGY (2017)
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
Jeffrey A. Jones et al.
LANCET HAEMATOLOGY (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Kirsten Fischer et al.
BLOOD (2016)
Breakthrough therapies in B-cell non-Hodgkin lymphoma
C. Y. Cheah et al.
ANNALS OF ONCOLOGY (2016)
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
Paul M. Barr et al.
BLOOD (2016)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With First-Line Idelalisib Plus Rituximab After Cessation of Treatment for Toxicity
Philip A. Thompson et al.
CANCER (2016)
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]-quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
William J. Scott et al.
CHEMMEDCHEM (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia
Jennifer R. Brown
SEMINARS IN ONCOLOGY (2016)
Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment
Paolo Ghia et al.
BLOOD (2016)
Idelalisib-associated Enterocolitis Clinicopathologic Features and Distinction From Other Enterocolitides
Christine Y. Louie et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Idelalisib-associated Colitis Histologic Findings in 14 Patients
Anna-Sophie Weidner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
Chan Yoon Cheah et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
K. Balakrishnan et al.
LEUKEMIA (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Management of Chronic Lymphocytic Leukemia in the Elderly
Jacqueline C. Barrientos
CANCER CONTROL (2015)
Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease
Timothy D. Cushing et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
Shuai Dong et al.
BLOOD (2014)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
PI3Kδ Inhibition Hits a Sensitive Spot in B Cell Malignancies
Bart Vanhaesebroeck et al.
CANCER CELL (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
HAEMATOLOGICAL CANCER Idelalisib-targeting PI3Kδ in patients with B-cell malignancies
Jan A. Burger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor
Rossana Maffei et al.
PLOS ONE (2014)
Apoptosis inducers in chronic lymphocytic leukemia
Christian Billard
ONCOTARGET (2014)
Two Birds with One Stone: Dual p110δ and p110γ Inhibition
Klaus Okkenhaug
CHEMISTRY & BIOLOGY (2013)
The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
Stefania Fiorcari et al.
PLOS ONE (2013)
B cell receptor signaling in chronic lymphocytic leukemia
Jan A. Burger et al.
TRENDS IN IMMUNOLOGY (2013)
First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies
Mark C. Lanasa et al.
BLOOD (2013)
Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Sven De Vos et al.
BLOOD (2013)
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Matthew S. Davids et al.
BLOOD (2012)
The B-cell receptor signaling pathway as a therapeutic target in CLL
Jennifer A. Woyach et al.
BLOOD (2012)
PI3K signalling: the path to discovery and understanding
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia
Jan A. Burger
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies
Marie O'Farrell et al.
BLOOD (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Markus K. Muellner et al.
NATURE CHEMICAL BIOLOGY (2011)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases
Ana V. Miletic et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
The PI3K Isoforms p110α and p110δ Are Essential for Pre-B Cell Receptor Signaling and B Cell Development
Faruk Ramadani et al.
SCIENCE SIGNALING (2010)
Relevance of the Immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
Katherine I. Lin et al.
BLOOD (2009)
Depletion of CD4+CD25+ human regulatory T cells in vivo:: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro
Karsten Mahnke et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Wnt-5a induces Dishevelled phosphorylation and dopaminergic differentiation via a CK1-dependent mechanism
Vitezslav Bryja et al.
JOURNAL OF CELL SCIENCE (2007)
Cutting edge:: The phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cells
Daniel T. Patton et al.
JOURNAL OF IMMUNOLOGY (2006)
Key role of the p110δ isoforrn of PI3K in B-cell antigen and IL-4 receptor signaling:: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells
A Bilancio et al.
BLOOD (2006)
Signalling by PI3K isoforms: insights from gene-targeted mice
B Vanhaesebroeck et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex
ST Jou et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation
E Hirsch et al.
SCIENCE (2000)
分享论文
